PubMed Health⌕ Search

Biomedical subjects

B Steinke

Publications and source records attributed to B Steinke.

53 records · Page 3Linked to original sources
PubMed1986

[Significance of clinical and laboratory chemical parameters for the course and prognosis of non-Hodgkin's lymphomas].

Using a regression model, the prognostic significance of clinical and biochemical parameters as well as of histology was analyzed in a group of 336 patients with Non-Hodgkin's lymphoma. A stochastic process model was used for evaluation of the course of disease. With respect to overall survival, serum-LDH-activity, performance status, and the histologically defined grade of malignancy were found to be the most important prognostic parameters, as well as age, though that to a lesser extent. In the course of disease, stage was the most relevant factor for achievement of a complete remission. In patients without remission, survival was determined mainly by histology and serum-LDH-activity; the latter was also of importance for duration of remission. Our study shows that histology is not the only prognostic factor in NHL but that other parameters, mainly serum-LDH-activity and performance status, also have to be considered in comparing different groups of patients.

Age Factors↗
PubMed1986

Mitoxantrone and VP-16 in refractory acute myelogenous leukemia.

Phase I/II-studies suggested that mitoxantrone is effective in the treatment of acute leukemia. In this study we have investigated its efficacy in combination with VP-16 in patients with refractory acute myelogenous leukemia. The regimen consists of: mitoxantrone 10 mg/m2/day i.v. from days 1 to 5, VP-16 100 mg/m2/day as short infusion from days 1 to 3. A dosis escalation of VP-16 was attempted. As of August 1985, 27 patients have been enrolled in the study and 21 patients are now evaluable. Of these 21 patients, 6 (28.6%) have achieved complete remission including 3 with primary refractory disease, 2 with early relapse (less than 6 months after CR), and 1 with relapse under maintenance therapy. Two other patients have attained a partial remission. Toxicity was mild and, except one case of early death, no life threatening complications were observed. This combination seems to be an active regimen in refractory acute myelogenous leukemia and its incorporation in front line therapy seems warranted.

Adolescent↗
PubMed1985

Melphalan-resistant multiple myeloma: results of treatment according to the M-2 protocol.

A group of 46 patients with melphalan-resistant multiple myeloma was treated according to the M-2 protocol with melphalan, prednisolone, BCNU, cyclophosphamide, and vincristine. According to the Salmon and Durie classification, four patients had stage II A; 36, stage III A; and six, stage III B disease. Treatment resulted in five patients (11%) entering remission, while 21 (46%) had stable and 20 (43%) had progressive disease. The median survival for all patients was 12.5 months, patients in remission surviving longer (median 46 months) than those with stable disease (median 15.4 months) or progressive disease (median 6.9 months). Compared with other treatment regimens used in melphalan-resistant myeloma, the remission rate is low but the median survival exceeds that reported by most other authors.

Adult↗
PubMed1984

[Therapy of multiple myeloma. Results of sequential treatment with melphalan-prednisolone and the M2 protocol].

Melphalan and prednisolone were intermittently used for treatment of 101 patients with multiple myeloma. In case of progression, either initially or after remission or after a phase of stabilisation, treatment was changed to the M-2 protocol. By primary treatment, remission was obtained in 24 patients, a stable phase in 47 patients. The treatment of second choice which became necessary in a total of 46 patients led to remission in 5 patients (11%), 21 (46%) became stabilised and in 20 (43%) the disease progressed. The median survival time for all 101 patients was 40.5 months after commencement of treatment. In patients with remission it was clearly longer (67 months) than in those with stable disease (38.1 months) or in those with progression (16.8 months). The mean time of survival after commencement of treatment of second choice was 12.5 months. Compared to other studies the remission rates are slight, the time of survival, however, is very remarkable. The overall survival rates are equivalent to the results thus far obtained by more aggressive treatment schemes.

Adult↗
PubMed1983

[Combined chemo- and radiotherapy of small cell bronchial carcinoma with high dosages of radiation].

35 patients with small cell carcinoma of the lung were treated with adriamycin, cyclophosphamide and vincristine according to the ACO-protocol. Between the third and fourth course of chemotherapy the primary tumor region was irradiated with a dose of 50 to 60 Gy. In addition, the cranium and the parts of the mediastinum, which were not yet invaded by the tumor received irradiation with 30 Gy. The complete remission rate was 71% (10 out of 14 patients) in limited disease and 29% (6 out of 21 patients) in extensive disease. The median survival time was 13 months in LD and 7 in ED. The relapses occurred mainly outside the fields of the radiation. Only 3 of the 16 patients who achieved a complete remission relapsed in the irradiated field. In contrast to the results obtained with combined chemo- and radiotherapy with doses of only 30-40 Gy to the primary area, there was better local control of the tumor but without a better remission rate or survival time. The toxicity was not increased by the high dose irradiation.

Adult↗
PubMed1983

[Chemotherapy of nonseminomatous testicular tumors. The results of a pilot study with reduced cis-platin dosage].

23 patients with non-seminomatous germ cell tumors of the testis were treated with Cis-Platinum 50 mg/m2 body surface on day 1, Vinblastine 0,4 mg/kg body weight in two doses on days 1 and 2, and Bleomycin 30 mg daily as continuous infusion (days 2-5). 7 patients were treated adjuvant after retroperitoneal lymphadenectomy. One of these had a relapse, he again received the same therapy and now has a complete remission. All other adjuvant treated patients are free of tumor. Of the 16 patients with large retroperitoneal and/or lung metastases, 10 (62%) had a complete remission, 2 of them after resection of persistent metastases after chemotherapy. 4 of the 10 patients with complete remission relapsed. In two patients with relapse a new complete remission could be established by the same chemotherapy. The remission rates achieved with this therapy with a relatively low dose of Cis-Platinum are similar to those obtained with higher doses of this agent. It is possible that there are more relapses, but these respond well to further treatment. Thus, the survival times of the patients treated with this protocol are similar to those reported in the literature. It is concluded that this regimen is an effective treatment in non seminomatous germ cell tumors.

Bleomycin↗
PubMed1983

[Combination treatment of small cell bronchial carcinoma].

35 cases with micro-cellular bronchial carcinoma are described. The patients are treated with a combination of a modified ACO scheme and fractionated irradiations with 50 to 60 Gy to the primary tumor and 30 Gy to the encephalic skull. Among 14 patients with local disease, ten had a complete remission and three a partial remission. Among 21 patients with advanced disease, six had a complete remission and eight a partial remission. The side effects were not important, and they were not reinforced by the higher dose of the primary irradiation. The local recurrence rate was decreased, but the average survival times were not prolonged, because these are still dependent upon the hematogenic formation of metastases.

Adult↗
PubMed1981

[Non-Hodgkin lymphoma with gastrointestinal manifestations].

The gastrointestinal tract is one of the most frequent places of manifestation of an extranodal non-Hodgkin's lymphoma. We have collected the dates of 27 patients--14 men and 13 women--with non-Hodgkin's lymphoma of the gastrointestinal tract. The age of the patients varied widely, the 7th decade being the most represented one. The stomach was the most frequent place of manifestation. In 2 cases the lymphoma spread over the whole gastrointestinal tract. At the time of diagnosis 12 patients had already reached stage IV. The histologic examination according to the Kiel-classification showed 11 lymphomas of low malignancy and 6 lymphomas of high malignancy. The prognosis was essentially determined by the stage, less by the histologic type of the lymphoma. Finally the possibilities of therapy are discussed.

Aged↗
PubMedDate not supplied

A counting process approach to the analysis of the course of non-Hodgkin's lymphoma.

Non-Hodgkin's lymphoma is a neoplastic disease with a course including remission and relapse. Therefore, a mortality analysis of overall survival time alone may conceal important differences between the forces of mortality (hazard functions) associated with distinct states of active disease, for example pre-remission state and first relapse. Further, prognostic factors for overall survival time may fail to contribute significantly to the pre-remission force of mortality. Our approach to analysis is based on a non-homogeneous Markov illness-death process as a stochastic model of the course of disease. It exploits the statistical theory of counting processes.

Humans↗
PubMedDate not supplied

Biological activity of novel macrocyclic alkaloids (budmunchiamines) from Albizia amara detected on the basis of interaction with DNA.

Extracts derived from Albizia amara were found to demonstrate activity in a recently developed hplc system designed to detect compounds capable of interacting with DNA. Further investigation led to the procurement of four sets of alkaloid isolates X1-X4 that were found to be macrocyclic pithecolobine alkaloids. All four isolates interacted with calf thymus DNA and were generally cytotoxic with a battery of cultured mammalian cells. As determined with Salmonella typhimurium strain TM677, isolates X1 and X3 were bactericidal, but not mutagenic. Isolate X1 was found to inhibit the catalytic activity of DNA polymerase, RNA polymerase, and HIV-1 reverse transcriptase. With DNA polymerase, the reaction was shown to be inhibited in a manner that was competitive with respect to DNA. In addition, isolate X1 inhibited each of the following: platelet aggregation, human lymphocyte transformation, phorbol-ester-induced chemiluminescence with human granulocytes, and cyclooxygenase activity. Detection of these alkaloids on the basis of their interaction with DNA exemplifies the validity of this approach.

Alkaloids↗
PubMedDate not supplied

Enhanced antigenicity of autologous leukemia cells enriched with cholesterylhemisuccinate.

Cholesterylhemisuccinate (CHS) has been used by different authors to enhance the antigenicity of tumor cells in human and in animals. In the present study, leukemic cells isolated mainly from patients with chronic myeloid and chronic lymphocytic leukemia were incubated for 90 min at 37 degrees in PBS containing 3.5% polyvinylpyrrolidone, 0.5% glucose, 1% human serum albumin and 150 micrograms/ml CHS 5 x 10(6) pretreated, irradiated, autologous leukemic cells were tested for their ability to elicit a delayed type hypersensitivity skin reaction. The negative controls included CHS-treated and untreated non-leukemic autologous blood cells as well as substance controls. Recall antigens such as tetanus, diphtheria and tuberculine included in the Multitest Mérieux served as positive controls. Results from 28 patients and 44 skin tests are presented. 19 of 23 patients tested under the best of experimental conditions generated a positive skin reaction with the CHS-treated autologous leukemic cells. Less than 12% of the patients reacted with any of the above negative controls. Under the same conditions, more than 90% of the CLL patients were reactive. 5 CLL patients were selected for a treatment including 6 weekly injections of 5 x 10(6) to 5 x 10(8) autologous CLL cells. 3 patients experienced an up to 60% reduction of their initial leukocyte counts. In one patient, the leukocyte counts continued to decrease more than 6 months after the treatment was completed. One patient showed no response and in one patient with increasing leukocytes this increase could not be reversed. The results are discussed in terms of earlier observations that membrane sterol content influences the presentation of cell surface proteins.

Acute Disease↗